Black pepper is widely known as a common culinary spice, yet its major bioactive compound, piperine, is increasingly attracting scientific interest for its potential health benefits. Acute leukemia is a rapidly progressing hematologic malignancy characterized by abnormal proliferation of white blood cells and often leads to severe complications such as anemia and thrombocytopenia. Current treatments, including chemotherapy and hematopoietic stem cell transplantation, can be effective but are often associated with significant side effects and high treatment costs. As a result, natural compounds with relatively low toxicity are becoming an important focus in oncology research. A recent study published in Scientific Reports explored the molecular mechanisms underlying the anti-leukemia effects of piperine. The findings suggest that piperine can selectively inhibit leukemia cell proliferation, induce apoptosis, and enhance the efficacy of chemotherapy drugs while showing minimal toxicity to normal cells. The study further identified cathepsin D and extracellular vesicle signaling as key mediators of this process, highlighting new possibilities for natural compounds in leukemia research and potential supportive therapeutic strategies.
Selective Inhibition of Leukemia Cells With Low Toxicity to Normal Cells
As an indispensable seasoning on dining tables, the pungent flavor of black pepper is well known. However, few people realize that its core active compound, piperine, may possess potential anti-cancer properties. Acute leukemia is a rapidly progressing hematologic malignancy characterized by the excessive proliferation of abnormal white blood cells, often leading to severe complications such as anemia and thrombocytopenia. Existing treatment options, including chemotherapy and transplantation, not only have significant side effects but also involve high treatment costs. Natural compounds, due to their relatively high safety and low side effects, have become a major focus of research in cancer therapy.
Recently, a study published in Scientific Reports further explored the molecular mechanisms underlying the anti-acute leukemia activity of piperine, bringing renewed attention to the medicinal potential of this common culinary spice.
Using the MTT assay, the research team found that piperine significantly inhibited the proliferation of NB4 acute promyelocytic leukemia cells and MOLT-4 T-cell acute lymphoblastic leukemia cells, with the effect increasing with higher doses and longer treatment times. After 24 hours, the half-maximal inhibitory concentration (IC50) was 224 μM for NB4 cells and 384 μM for MOLT-4 cells. After 48 hours, the IC50 values decreased to 145 μM and 156 μM, respectively. Notably, piperine had almost no effect on the proliferation of normal peripheral blood mononuclear cells, demonstrating good cellular selectivity and providing a safety basis for further potential clinical exploration.
Figure: Dose-dependent inhibitory effects of piperine on NB4 and MOLT-4 cells after 24 and 48 hours.
Mechanistic Insights: Apoptosis Induction and Synergy With Chemotherapy
When piperine was combined with daunorubicin, a commonly used clinical chemotherapy drug, the researchers observed a significant synergistic anti-cancer effect. MTT assay results showed that leukemia cell viability in the combination treatment group was markedly lower than in groups treated with piperine or daunorubicin alone. Using CompuSyn software, the calculated combination index was 0.59 in NB4 cells and 0.81 in MOLT-4 cells, both less than 1, confirming the synergistic interaction. This finding suggests that combination therapy in the future might allow lower doses of chemotherapy drugs while improving therapeutic efficacy and reducing adverse effects, potentially easing the treatment burden for patients.
Figure: Synergistic effects of piperine and daunorubicin in NB4 and MOLT-4 cells.
To clarify the mechanism of action, the researchers used Annexin V-FITC/PI double-staining flow cytometry and found that the apoptosis rate of NB4 and MOLT-4 cells significantly increased after 48 hours of piperine treatment. Further cell-cycle analysis revealed a notable increase in the proportion of cells in the sub-G1 phase in both cell lines following treatment, indicating DNA fragmentation. These results confirm that piperine exerts its anti-cancer effects primarily by inducing apoptosis, a form of programmed cell death that effectively interrupts the abnormal proliferation cycle of leukemia cells.
Through bioinformatics analysis using the STITCH and ChEMBL databases, the research team predicted 39 piperine-responsive proteins. By integrating these predictions with proteomic data from leukemia-derived extracellular vesicles, two candidate proteins were identified: cathepsin D and NPC1. Protein-protein interaction network analysis further revealed that only cathepsin D interacted with apoptosis-related proteins CASP3 and BID. To validate this finding, cells were pretreated with the cathepsin D inhibitor pepstatin A. The results showed that inhibition of cathepsin D significantly reduced the apoptosis rate induced by piperine in leukemia cells, confirming that cathepsin D is a key target protein mediating piperine-induced apoptosis.
Figure: The cathepsin D inhibitor pepstatin A reduces piperine-induced apoptosis in NB4 and MOLT-4 cells.
Extracellular vesicles serve as important carriers for the transmission of biological information between cells and play a key role in leukemia progression. The researchers successfully isolated and characterized extracellular vesicles released from leukemia cells after piperine treatment.
Although their size was similar to those from untreated cells, their release quantity increased significantly, and they expressed typical extracellular vesicle markers such as CD9, CD63, and flotillin-1.
When these vesicles from piperine-treated cells were co-cultured with leukemia cells, RT-qPCR and Western blot analyses showed significantly higher mRNA and protein expression levels of cathepsin D, Bax, and caspase-3 compared with the control group. These findings indicate that piperine may enhance anti-cancer effects by modulating the composition of extracellular vesicle cargo and amplifying apoptotic signaling.
Figure: Extracellular vesicles derived from piperine-treated cells enhance the expression of cathepsin D and pro-apoptotic genes and proteins in NB4 and MOLT-4 cells.
Conclusion
This study systematically elucidates the anti-acute leukemia effects of piperine, the active compound found in black pepper, at the molecular level. Piperine not only selectively inhibits leukemia cell proliferation and induces apoptosis but also demonstrates synergistic effects when combined with chemotherapy drugs, while exhibiting very low toxicity toward normal cells.
The core mechanism involves targeting cathepsin D, upregulating pro-apoptotic molecules such as Bax and caspase-3, and promoting the release of functional extracellular vesicles from leukemia cells to amplify apoptotic signaling.
These findings highlight previously underappreciated medicinal properties of the common culinary spice black pepper. With further in vivo experiments and clinical research, piperine may potentially serve as a complementary or combination therapeutic option for acute leukemia, offering new directions for improving patient outcomes and reducing treatment costs, while also providing valuable insights into the application of natural compounds in cancer research.